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The human pathogen, group A rotavirus, is the most prevalent cause of acute infantile and pediatric gastroenteritis worldwide, 
especially in developing countries. There is an urgent demand for safer, more effective and cheaper vaccines against rotavirus 
infection. Plant-derived antigens may provide an exclusive way to produce economical subunit vaccines. Virus-like particles, 
constituting viral capsid proteins without viral nucleic acids, are considered a far safer candidate compared with live attenuated 
viral vaccines. In this study, the rotavirus capsid proteins VP2, VP6 and VP7 were co-expressed in transgenic tobacco plants, 
and their expression levels, formation of rotavirus-like particles (RV VLPs) and immunogenicity were extensively studied. 
Quantitative real-time RT-PCR and Western blot analysis revealed that the expression level of vp6 was the highest while vp7 
was expressed at the lowest levels. The RV VLPs were purified from transgenic tobacco plants and analyzed by electron mi-
croscopy and Western blot. Results indicated that the plant-derived VP2, VP6 and VP7 proteins self-assembled into 2/6 or 
2/6/7 RV VLPs with a diameter of 60–80 nm. When orally delivered into mice with cholera toxin as an adjuvant, the total 
soluble protein extracted from transgenic tobacco plants induced rotavirus-specific antibodies comparable with those of at-
tenuated rotavirus vaccines, while VP 2/6/7 induced higher serum IgG and fecal IgA titers compared with VP 2/6. 
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Rotavirus (RV) is the leading cause of severe infantile gas-
troenteritis, accounting for more than 125 million cases of 
diarrhea and causing 600000 deaths per year, mainly in de-
veloping countries [1]. In developed countries, dehydration 
in children suffering diarrhea caused by rotavirus infection 
is a common cause of hospitalization. The Global Alliance 
on Vaccines and Immunizations (GAVI) identified a rota-
virus vaccine as one of the top three priority vaccines for 
international development. 
Rotavirus belongs to the virus family Reoviridae, and is 
composed of three concentric protein layers surrounding 11 
segments of double-stranded RNA (dsRNA), each coding for 
products that are either viral structural proteins (VPs) or non-
structural proteins (NSPs). 60 dimers of VP2 comprise the 
inner core. The middle layer is formed by 260 trimers of VP6, 
which accounts for 50% of the total virus protein mass, is 
highly immunogenic and contains T-cell antigenic determi-
nants shared by various rotavirus types within group A [2,3]. 
 Yang Y M, et al.   Sci China Life Sci   January (2011) Vol.54 No.1 83 
 
The outer layer is composed of 260 trimers of the glycosy-
lated protein, VP7, with spikes formed by the 60 trimers of 
VP4. Individual VP4 or VP7 is able to induce the neutralizing 
antibody, which can passively protect mice against rotavirus 
challenge [4–8], so they are considered as targets for protec-
tive immunity in rotavirus vaccine development.  
The first RV vaccine, RotaShield, was composed of an 
attenuated reassortment strain and was licensed in the 
United States in 1998 [9]. However, the vaccine was with-
drawn from the market in less than a year because its deliv-
ery was associated with intussusception [10]. Recently, two 
RV vaccines, RotaTeq and Rotarix, were developed and 
shown to efficiently protect against severe diarrhea, how-
ever, they are produced using live attenuated RV strains 
[11–15]. Besides the side effects, live attenuated vaccines 
have the risk of possible virulence reversion. Intense efforts 
have been made for decades to develop more efficient and 
safer vaccines against RV, including DNA vaccines, but the 
IgG induced by DNA vaccination coding for VP4 or VP7 
fails to protect mice against RV challenge [16]. 
A novel vaccine strategy utilizing virus-like particles 
(VLPs) is developing rapidly. Virus-like particles consist of 
virus capsid proteins, hence they are morphologically simi-
lar to the native virus particles, and can trigger B and T cell 
responses [17,18]. Their compact structure likely protects 
them from degradation by digestive enzymes in the gut 
when orally delivered, as is the case with Norwalk VLPs 
[19]. Additionally, VLPs contain no genome, meaning that 
they are safer to use than conventional vaccines. 
Rotavirus-like particles (RV VLPs) have the potential to 
be highly immunogenic and safe vaccine candidates against 
RV infection, and have received substantial attention in 
recent years. Self-assembled RV VLPs composed of differ-
ent combinations have been produced by co-expressing the 
RV capsid proteins VP2, VP6 and VP7 with or without VP4 
in baculovirus-infected insect cells. The 2/6-VLPs in 
Freund’s adjuvant administered parenterally to rabbits af-
forded protection against RV challenge [20]. When admin-
istered intranasally (i.n.) with a mutant Escherichia coli 
heat-labile toxin (LT-R192G) or parenterally with QS-21, 
the 2/6-VLPs conferred full protection in adult mice against 
RV infection [21,22]. In a gnotobiotic pig model, which is 
an RV disease model that most closely mimics the human 
situation in terms of pathogenicity, i.n. immunization with 
2/6-VLPs did not confer protection against diarrhea upon 
challenge [23,24]. The 2/6/7- and 2/4/6/7-VLPs can prime 
the immune system against a broad range of homotypic or 
heterotypic RV challenges and induce anamnestic neutral-
izing antibody responses in mice and rabbits [25,26]. Addi-
tionally, i.n. immunization of mice with 2/6/7-VLPs results 
in passive protection of pups against RV infection [27]. 
However, the cost of production and delivery using a bacu-
lovirus expression system to produce RV VLPs, is too high 
for large-scale application, especially in poorer countries 
and areas. 
Expression of foreign antigens in plants provides an effi-
cient way to produce economical subunit vaccines, and 
plant-derived oral vaccines have been suggested as particu-
larly suitable for use, especially in poorer regions, due to 
ease of production, handling, and administration, without 
risk of being contaminated with animal pathogens [28–31]. 
At present the VLPs of several viruses have been produced 
in plants successfully, for example, human papillomavi-
rus-like particles and Norwalk VLPs in transgenic tobacco 
and potato plants, respectively [32–34]; cottontail rabbit 
papillomavirus-like particles in tobacco plants [35]; hepati-
tis B virus (HBV) VLPs in tobacco, soybean and potato 
plants [36,37]; rotavirus 2/6 VLPs in tomato plants [38]; 
recombinant HIV-1/HBV VLPs in tobacco and Arabidopsis 
plants [39]. In this study, we co-expressed three capsid pro-
teins, VP2, VP6 and VP7 of group A RV in tobacco plants. 
Plant extract-stimulated RV-specific serum IgG and intesti-
nal IgA in mice when delivered orally with cholera toxin 
(CT) and a portion of plant-expressed RV capsid proteins 
could assemble into double- and triple-layered RV VLPs 
that were morphologically and physically similar to native 
RV particles. 
1  Materials and methods 
1.1  Virus RNA extraction and plasmid construction  
Human group A RV (P[8]G1) dsRNA was extracted from 
stool specimens (T114) of infected children in Beijing, 
China. A 500 μL stool suspension was adjusted to contain 
1% sodium dodecyl sulfate and incubated at 56°C for 30 
min, centrifuged at 15294×g for 5 min at room temperature, 
and the supernatant transferred to a new tube and extracted 
once with phenol:chloroform (1:1). The aqueous phase was 
precipitated with two volumes of ethanol at −70°C over-
night, centrifuged at 15294×g for 15 min at 4°C. The RV 
dsRNA precipitate was resuspended in 100 μL water, and 
the concentration was determined by absorbance at 260 nm. 
The cDNAs of vp2, vp6 and vp7 were synthesized by re-
verse transcriptase, utilizing RV dsRNA and the primers 
vp2c, vp6c, vp7c (Table 1) and then cloned into plasmid 
pTZ18 at the Sma I site. Using the resultant plasmids as 
templates, full-length vp2, vp6 and vp7 with EcoR I and 
Hind III sites added at both terminals were obtained by po-
lymerase chain reaction (PCR) using primers vp2p, vp6p, 
vp7p (Table 1) and subcloned at the same sites into the 
pBI121 binary plasmid, downstream of the constitutive cau-
liflower mosaic virus (CaMV) 35S promoter (Figure 1). The 
resultant plasmids were transferred into Agrobacterium tu-
mefaciens strain LBA4404 by electroporation. 
1.2  Plant transformation and PCR analysis 
The leaf discs of axenic tobacco plants (Nicotiana tabacum  
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Table 1  Sequences of primers used in this study 
Primers Forward Reverse Position 
vp2c 5′-GGCTATTAAA GGCTCAATGGCG-3′ 5′-GGTCATATCTCCACAGTGGGGTTG-3′ 5′UTR-3′UTR 
vp6c 5′-CGCTTTAAAACGAAGTCTTCGAC-3′ 5′-GGTCACATCCTCTCACTACATC-3′ 5′UTR-3′UTR 
vp7c 5′-GGCTTTAAAAGAGAGAATTTC-3′ 5′-TCACATCATACAATTCTAATC-3′ 5′UTR-3′UTR 
vp2p 5′-ATATGGATCCATGGCGTACAGGAAGCGCGGAGC-3′ 5′-ATATGAGCTCGGCGTTTACAGTTCGTTCATAA-3′ 1-2703 
vp6p 5′-TAGGATCCATGGAGGTTTTATATTC-3′ 5′-TAGAGCTCTTAGTCTGGTCCTCAC-3′ 1-1206 
vp7p 5′-TAGGATCCATGTATGGTATTGAATATAC-3′ 5′-TTGAGCTCCTATACTCTATAATAAAAC-3′ 1-981 
vp2s 5′-ACAGGAAGCGCGGAACTAAAC-3′ 5′-TGCGACTAGCGACTCACGAAG-3′ 1604-2254 
vp6s 5′-CTCCACAATCTGAAGCGTTA-3′ 5′-TGCGGAAATAGTGCATTAACA-3′ 329-929 
vp7s 5′-AGGATCAATGGACACTG-3′ 5′-ATTAAGCCACCAACTTG-3′ 180-796 
vp2f 5′-ATGGCGTACAGGAAGCGCGGAA-3′ 5′-TTTACAGTTCGTTCATAATGC-3′ 1-2703 
vp6f 5′-ATGGAGGTTTTATATTCATTG-3′ 5′-TTAGTCTGGTCCTCACTTAATC-3′ 1-1206 
vp7f 5′-ATGTATGGTATTGAATATACCAC-3′ 5′-CTATACTCTATAATAAAACGCAG-3′ 1-981 
vp2re 5′-TCTGGCCGGCATAAATTCACAAG-3′ 5′-TGCG ACTAGCGACTCACGAAGAAAC-3′ 1167-1348 
vp6re 5′-GGTACAACACTTTTAAATTTGGATG-3′ 5′-GCTAATTTTCTTAACGCTTCAGATT-3′ 202-362 
vp7re 5′-ACAATCGGGAGAATCAAATAAGTGGA-3′ 5′-TCAGCAACCGTTTCAAATGAGTCTAC-3′ 573-710 




Figure 1  Constructs for plant expression cassettes. The genes vp2, vp6 or vp7 were cloned into the T-DNA region of the binary vector, pBI121, which 
contained the neomycin phosphotransferase gene (nptII) for kanamycin resistance. 35S, CaMV promoter; NOS, terminator; LB, left border; RB, right border. 
cv. SR I) were co-cultured with A. tumefaciens strains 
LBA4404 containing three plant expression vectors simul-
taneously and grown on Murashige and Skoog (MS) me-
dium containing kanamycin (100 μg mL−1) to regenerate 
plants. Kanamycin-resistant plants were transplanted to soil 
and grown under standard conditions in a greenhouse. 
Regenerated kanamycin-resistant tobacco plants were 
further selected by PCR. Genomic DNA of kanamy-
cin-resistant plants was isolated using cetyl trimethyl am-
monium bromide (CTAB). The PCRs were performed using 
the specific primers vp2s for vp2, vp6s for vp6 and vp7s for 
vp7 (Table 1). Plasmid pBI221 containing the vp2, vp6 or 
vp7 genes and the DNA of non-transgenic tobacco plants 
were used as the positive and negative controls, respectively. 
The amplified products were analyzed by electrophoresis on 
a 1% (w/v) agarose gel. 
1.3  Reverse transcription PCR (RT-PCR) and quanti-
tative real-time RT-PCR (qPCR)  
To detect if genes were correctly transcribed, total plant 
RNA was extracted from transgenic or non-transgenic to-
bacco plants using Trizol reagent (Invitrogen, Carlsbad, CA, 
USA). Exactly 2 μg of total plant RNA was used in a re-
verse transcription (RT) reaction according to a protocol 
from Promega (Madison, WI, USA), and 2.5 μL of the RT 
reaction mixture was used to amplify the full length of each 
gene by PCR with specific primers vp2f for vp2, vp6f for 
vp6 and vp7f for vp7 (Table 1). The amplified products 
were separated by electrophoresis on a 1% (w/v) agarose 
gel. For quantitative analysis of the vp2, vp6 and vp7 RNA 
transcripts in transgenic tobacco plants, the cDNAs of each 
transcript were further analyzed by qPCR. A 2 μL volume 
of the RT reaction mixture was added to a 25 μL PCR mix-
ture containing 12.5 μL Real-time PCR Master Mix 
(TOYOBO) and 0.3 μmol L−1 primers (Table 1). The Nico-
tiana benthamiana EF1α mRNA (GenBank accession No. 
CN744397) was utilized as an internal control using primers 
EF (Table 1). The qPCR was carried out on an Opticom II 
(Bio-Rad, Hercules, CA, USA) using the following thermal 
cycling profile: 95°C for 1 min, followed by 40 cycles of 
amplification (95°C for 30 s, 60°C for 30 s and 72°C for 30 
s). All samples were run in triplicates. 
1.4  Total soluble protein extraction and Western blot 
analysis 
A 1 g mass of leaves from transgenic or non-transgenic to-
bacco plants was ground in a mortar in the presence of liq-
uid nitrogen. The resulting powder was added to 3.3 mL 
phosphate-buffered saline (PBS; 0.15% Na2HPO4, 0.04% 
KH2PO4, 0.61% NaCl, pH 7.2) with 0.1% Triton X-100 and 
33 μL protease inhibitor cocktail (Sigma, St. Louis, MO, 
USA). After gentle vortexing, the mixture was centrifuged 
at 15294×g for 15 min at 4°C and the supernatant was col-
lected. The total soluble protein (TSP) was quantified using 
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a protein assay kit (Bio-Rad). 
For Western blot analysis, 80 µg TSP was separated on a 
10% SDS-PAGE gel and transferred to PVDF membrane 
(Millipore), the membrane was blocked with 3% bovine 
serum albumin (BSA) for 2 h and sequentially probed with 
goat anti-RV polyclonal antibody (1:3000; Abcam) for 1 h. 
After rinsing the membrane to remove the unbound primary 
antibody, the membrane was incubated with an alkaline 
phosphatase-conjugated chicken anti-goat IgG (1:3000; 
Bios) for 1 h. After rinsing the membrane again, NBT/BCIP 
(Promega) was added for color development following the 
directions provided by the company. 
1.5  Purification of RV VLPs from transgenic tobacco 
plants and electron microscopy analysis 
To purify RV VLPs, 5 g of leaves from transgenic or 
non-transgenic tobacco plants was ground to a fine powder 
in liquid nitrogen and added to 16 mL extraction buffer (10 
mmol L−1 Tris-HCl, pH 7.5, 140 mmol L−1 NaCl, 0.1% Tri-
ton X-100) with 160 µL protease inhibitor cocktail (Sigma). 
The sample was gently mixed by inversion and centrifuged 
twice at 15294×g for 15 min at 4°C, then 4 mL of super-
natant was loaded onto an 8 mL 40% sucrose cushion in 
TNC buffer (10 mmol L−1 Tris-HCl, pH 7.5, 140 mmol L−1 
NaCl, 10 mmol L−1 CaCl2) with 80 μL protease inhibitor 
cocktail (Sigma) and centrifuged in a Beckman SW41Ti 
rotor at 150000×g for 3 h at 4°C. The pellet was resus-
pended in 500 μL TNC buffer and the supernatant was also 
collected for Western blot analysis as described above. 
For negative staining, resuspended pellets were placed on 
Formvar-carbon coated copper grids, stained for 10 min 
with 3% phosphotungstic acid and viewed with a JEM-1400 
transmission electron microscope. 
1.6  Vaccination 
For immunization analysis, 40 RV-negative female BALB/c 
mice (eight-week-old, purchased from The Academy of 
Military Medical Sciences, Beijing, China) were divided 
randomly into five groups and immunized orally with the 
TSP extracted from transgenic or non-transgenic tobacco 
plants or PBS in a final volume of 300 μL mixed with 10 µg 
CT as an adjuvant, or 200 μL live oral attenuated RV vac-
cine (Lanzhou Institute of Biological Products) on days 0, 7, 
14 and 21. Mice were starved overnight and gavaged with 
30 μL of 7.5% bicarbonate buffer (Gibco) immediately 
prior to oral inoculation in order to neutralize stomach acid-
ity. In groups I (VP 2/6) and II (VP 2/6/7) each mouse was 
administered TSP extracted from VP 2/6 or VP 2/6/7 trans-
genic tobacco plants, respectively, containing 25 μg VP6. In 
groups III (WT) and IV (PBS) each mouse was gavaged 
with TSP extracted from non-transgenic tobacco plants or 
PBS as a negative control. In group V (RV), each mouse 
was gavaged with a live oral attenuated RV vaccine. All 
mice were kept in micro isolator cages (Experimental Ani-
mal Center, Institute of Genetics and Developmental Biol-
ogy, Chinese Academy of Sciences, Beijing, China) during 
the whole experiment, and no clinical change was observed 
in all mice. 
Serum was collected by tail bleeding at 0, 28, 35 and 43 
days post-immunization (DPI) and stored at −20°C. Fecal 
samples collected from individual mice 0, 28, 35 and 42 
DPI were made into a 10% (w/v) suspension in 0.01 mol 
L−1 PBS containing a protein inhibitor cocktail (Sigma), and 
centrifuged to remove fecal solids. Processed fecal samples 
were stored at −20°C. 
1.7  Detection of antibody responses by enzyme-linked 
immunosorbent assay (ELISA) 
Rotavirus-specific total antibodies (IgA, IgM, IgG), IgG or 
IgA present in mouse serum or fecal samples were measured 
by ELISA. To measure total antibodies to RV, microtiter 
plates were coated with 500 ng RV at 4°C overnight, washed 
three times with PBST (PBS with 0.5% Tween 20), blocked 
with PBST containing 2% BSA at 37°C for 2 h, and washed 
three times. Samples were serially diluted two-fold and in-
cubated at 37°C for 2 h. Following another wash, horserad-
ish peroxidase-conjugated goat anti-mouse IgA, IgM, and 
IgG (ICLLab, 1:3000 dilution) were added and the plates 
were incubated at 37°C for 2 h. After a final wash, the sub-
strate OPD was added and incubated for 10 min at 37°C. The 
reaction was terminated with 2 mol L−1 H2SO4 and the ab-
sorbance at 492 nm (A492) was determined. 
For measurement of anti-RV serum IgG and fecal IgA, 
the coating, blocking, washing, and addition of samples 
were performed in an identical manner as for the total anti-
body ELISA described above. After washing away the se-
rum samples, the plates were incubated with horseradish 
peroxidase-conjugated goat anti-mouse IgG or IgA (ICLLab, 
1:3000) at 37°C for 2 h. After a final wash, OPD was added 
and the A492 determined. Antibody titers were defined as the 
reciprocal of the highest dilution giving an A492 that was at 
least two-fold the mean A492 of samples from the negative 
controls. 
2  Results 
2.1  Selection of transgenic plants 
In total, 175 independent kanamycin-resistant transgenic 
lines were obtained. These plants were primarily screened 
by PCR with specific primers for vp2, vp6 and vp7. We 
found that the majority of transgenic lines contained two 
genes, vp6 and vp7, and several plants contained vp2, but 
only one plant contained all three genes. This plant was 
allowed to self-pollinate to obtain T1 generation plants 
containing VP 2/6 or VP 2/6/7, which were finally used to 
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carry out immunization experiments. 
2.2  Analysis of RV gene transcripts 
Transcription of RV genes vp2, vp6 and vp7 in transgenic 
tobacco plants was analyzed by RT-PCR with specific 
primers for each gene. As Figure 2 shows, full-length vp2 
(2703 bp), vp6 (1206 bp) and vp7 (981 bp) were detected in 
total RNA by RT-PCR, having the same size as the corre-
sponding positive control. By contrast, PCR amplification 
of total RNA preparations from non-transgenic tobacco 
plants did not display the relevant bands. The accumulation 
of vp2, vp6 and vp7 mRNAs in transgenic tobacco plants 
was estimated by qPCR. The housekeeping-gene EF1α was 
used as an internal control and the RNA extracted from 
non-transgenic tobacco plants was used as a negative con-
trol. Plasmids containing vp2, vp6 or vp7 were used as posi-
tive controls for each qPCR, respectively. Relative quantity 
analysis indicated the amount of vp6 mRNA was 500 times 
more than that of vp7 or vp2, and the amount of vp7 mRNA 
was lowest (Figure 3). 
2.3  Analysis of RV proteins produced in tobacco plants 
Crude protein extracts from transgenic tobacco leaves were  
 
 
Figure 2  RT-PCR detection of vp2, vp6 and vp7 mRNAs. Lane 1, PCR 
products from corresponding plasmid DNAs (positive controls). Lane 2, 
RT-PCR products from total RNA extracted from non-transgenic tobacco 
plants (negative controls). Lane 3, RT-PCR products from total RNA of  
transgenic tobacco plants. M, a molecular weight ladder. 
 
Figure 3  Relative quantification of accumulation of vp2, vp6 and vp7 
mRNAs as measured by qPCR in transgenic tobacco plants. Housekeeping  
gene EF1α was used as an internal control. 
used in the Western blot analysis and probed with anti-RV 
polyclonal antibody (Figure 4). VP2, VP6 and VP7 were 
clearly detected in transgenic tobacco plants at their ex-
pected sizes of 84 (VP2), 45 (VP6) and 37 kD (VP7), and 
no relevant band was found in proteins extracted from 
non-transgenic tobacco plants. Protein quantification was 
achieved by Western blot techniques. The amount of each 
protein was normalized to VP7 expressed in E. coli at a 
known protein concentration, which was related to the cor-
responding band density, allowing a comparison between 
different protein amounts. The amount of VP6 was greatest, 
accounting for up to 1.5‰ of the TSP, obviously as a result 
of its high transcript levels. 
2.4  Co-expressed VP2, VP6 and VP7 in transgenic to-
bacco plants assemble into RV VLPs 
To purify RV VLPs, the crude protein extract of transgenic 
tobacco leaves was centrifuged through a 40% sucrose 
cushion and the supernatant and pellet were collected. The 
pellet was resuspended and negatively stained with 3% 
phosphotungstic acid and observed by electron microscopy. 
As expected, spherical particles with a 60–80 nm diameter 
were found (Figure 5A–D), which were very similar in ap-
pearance to native RV particles (Figure 5E). No such parti-
cle was found in the pellet purified from the protein of 
non-transgenic tobacco leaves (Figure 5F). This result indi-
cated that co-expressed VP2, VP6 and VP7 proteins in to-
bacco plant cells could interact with each other and assem-
ble into authentic icosahedral RV VLPs. 
The pellet and supernatant obtained above were further 
analyzed by Western blot with an anti-RV polyclonal anti-
body. As shown in Figure 6, when the pellet sample was 
incubated at 37°C for 10 min before loading, no monomer 
protein was detectable. When the pellet sample was boiled  
 
 
Figure 4  Western blot analysis of TSP in transgenic tobacco plants. TSP 
was extracted from tobacco plants transformed with vp2, vp6 and vp7 
(2/6/7) or non-transgenic tobacco plants (WT). The protein samples were 
denatured by heating at 100°C for 10 min before loading and probed with  
the goat anti-RV polyclonal antibody. 
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for 10 min before loading, VP2, VP6 and VP7 monomers 
were reliably detected. The stoichiometric mass ratio of 
VP2:VP6:VP7 in the pellet was 1:4.26:0.77, biased from 
that in the native RV particle, which was 1:2.8:2.4 (Table 
2). The outer-layer protein, VP7, may only partially exist or 
be completely absent in some RV VLPs. Obviously, both 
2/6 VLPs and 2/6/7 VLPs existed in the pellet, but they 
could not be distinguished by electron microscopy. Large 
amounts of VP2, VP6 and VP7 monomers were present in 
the supernatant (Figure 6), which meant most of the viral 
capsid proteins did not assemble into RV VLPs. Based on 
the result of comparing the stoichiometric mass of dissocia-
tive RV proteins in the supernatant with that in the pellet, it 
can be concluded that only a small portion of RV capsid 
proteins produced in transgenic tobacco plants assembled 
into RV VLPs. 
 
 
Figure 5  Detection of RV VLP purified from transgenic tobacco plants 
by electron microscopy. A–D, RV VLPs purified from tobacco plants 
transformed with vp2, vp6 and vp7. E, Native rotavirus particles. F, Nega- 
tive control from non-transgenic tobacco plants. Scale bar=50 nm. 
Table 2  Mass stoichiometric ratio of RV proteins 
 VP6:VP2 VP7:VP2 
In TSP 3.73 1.47 
In pellet 4.26 0.77 




Figure 6  Western blot analysis of RV VLPs purified from transgenic 
tobacco plants. A, Samples were incubated at 37°C for 20 min before 
loading. B, Samples were denatured by heating at 100°C for 10 min before 
loading. s, the sample taken from the supernatant; p, the sample taken from  
the pellet; ck, control from non-transgenic tobacco plants. 
2.5  Rotavirus capsid proteins produced in tobacco 
plants can induce humoral and mucosal immune re-
sponses in orally immunized mice 
Rotavirus antibody-negative BALB/c mice orally received 
four doses of crude soluble leaf extract from either trans-
genic or non-transgenic tobacco plants mixed with the mu-
cosal adjuvant, CT. Serum and fecal samples were collected 
on 28, 35 and 43 DPI from experimentally immunized mice 
and probed for the presence of RV-specific total antibodies 
by ELISA (Figure 7A and B). At 28 DPI, the total 
RV-specific antibody titers in serum and feces were low and 
did not differ significantly among mouse groups, then in-
creased steadily until 43 DPI. At 43 DPI, VP 2/6/7 group 
mice induced the highest ELISA titer of RV-specific total 
antibodies in both serum and fecal samples. 
Rotavirus-specific serum IgG was evaluated on 43 DPI 
(Figure 7C). Compared with mice inoculated with the con-
trol plant extract, both the VP 2/6 and VP 2/6/7 groups of 
mice developed significantly high serum IgG titers. Mean-
while, the level of rotavirus-specific IgG antibody detected 
in the sera of VP 2/6/7 group mice was significantly higher 
than in the sera of VP 2/6 and RV group mice. The serum 
IgG titer in the VP 2/6 group was almost as high as that 
detected in the RV group. 
Immunized mice were tested for presence of RV-specific 
intestinal IgA in processed fecal samples by ELISA (Figure 
7D). None of the mice immunized orally with extracts from 
control tobacco plants developed any RV-specific intestinal 
IgA responses. However, ELISA titers of mucosal IgA 
found in RV group mice were significantly higher than that 
in the VP 2/6 and VP 2/6/7 group mice. We also compared 
the effect of protein composition of orally administered VPs 
(VP 2/6 or VP2/6/7) on immunogenicity, and VP 2/6/7 was 
found to induce higher serum IgG and fecal IgA titers in 
mice when compared with VP 2/6. 
3  Discussion 
Vaccination is an efficient form of preventing transmission 
of infectious diseases. Considerations regarding the suitabil-
ity of vaccines revolve around their efficiency, safety, cost 
and delivery. For years, scientists have been seeking ways 
to produce vaccines with these qualities. Plant-based vac-
cines may be the solution to these problems, especially in 
the case of oral vaccines. Compared with prokaryotic ex-
pression systems, plants can properly handle the down-
stream processing of foreign proteins, including phosphory-
lation, glycosylation and folding, which is important for 
immunogenicity of an antigen protein. If oral vaccines are 
produced in edible parts of the plants, they can be delivered 
by the oral route directly without further processing, such as 
purification. Plant systems do not harbor human or animal 
pathogens; therefore, they do not transmit any pathogens  
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Figure 7  Immune responses in mice following mucosal oral immunization with TSP from transgenic tobacco plants. Total (IgA, IgG and IgM) serum (A) 
and fecal (B) anti-RV antibodies were measured in each group of mice at 28, 35, 43 DPI; RV-specific serum IgG (C) and fecal IgA (D) were measured in  
each group of mice at 43 DPI. 
 
that could be damaging to humans. 
The advantages of plant based subunit vaccines are in-
contestable, but many challenges remain, especially the 
efficiency of the vaccine. Using VLPs as antigens is a new 
strategy to produce higher efficiency subunit vaccines. 
VLPs produced in plant cells can provide stronger and 
longer-lasting vaccines, but the work to produce VLPs in 
plants is lagging. Up to now, the RV vaccines available on 
the market are live attenuated vaccines. To produce a safer 
and cheaper RV vaccine, the plant-based RV VLPs strategy 
designed by us involved three RV capsid protein genes in-
cluding vp2, vp6 and vp7, which were co-transformed into 
tobacco plants, and the transgenic plant containing vp2, vp6 
and vp7 was obtained. 
Mice orally immunized with TSP extracted from the 
transgenic tobacco leaves, with CT as an adjuvant, induced 
RV-specific antibodies comparable to those of an attenuated 
RV vaccine. The TSP containing VP 2/6/7 induced the 
highest serum IgG titer, while the replicating attenuated RV 
vaccine induced the highest intestinal IgA titer. The TSP 
containing VP 2/6/7 induced higher serum IgG and fecal 
IgA titers in mice compared with VP 2/6. This result does 
not exceed our expectations, since the VP7 was absent in 
the later samples. 
The RV VLPs were purified from transgenic tobacco 
leaves and observed by electron microscopy. Further West-
ern blot analysis indicated the particles comprised 2/6/7- 
and 2/6-VLPs. VP7-containing RV VLPs have not been 
obtained in plants previously. Many researchers have suc-
cessfully produced and purified RV VLPs in insect cells; 
however, the efficiency of assembly of RV VLPs in insect 
cells is very low, with only about 15% of the total virus 
capsid proteins produced in the insect cells participating in 
the formation of RV VLPs [40,41]. The self-assembly effi-
ciency of 2/6-RV VLPs produced in transgenic plants was 
even lower [38]. In this study, we came to the same conclu-
sion by comparing the stoichiometric mass of proteins in the 
supernatant with that in the pellet purified through a sucrose 
cushion. 
One important factor affecting the yield of RV VLPs 
may be the stoichiometric mass ratio of capsid proteins 
produced in the plant cell. For efficient RV VLP formation, 
the ratio of each capsid protein was significantly important 
[40,41]. In our study, both 2/6 and 2/6/7 RV VLPs were 
detected in the extract from transgenic tobacco plants. By 
comparing the stoichiometric mass ratio of VP2:VP6:VP7 
produced in tobacco plants compared with that in the native 
RV particle, we found that VP7 was under-expressed and it 
could be the limiting protein during the assembly of tri-
ple-layered particles. According to studies by Vieira and 
Carrondo [40,41], the outer layer protein VP7 should be 
more than VP2 and VP6 thus avoiding accumulation of 
waste monomers or other protein complexes, such as VP6 
trimers [42,43]. 
In conclusion, we co-expressed the RV capsid proteins 
VP2, VP6 and VP7 in tobacco plants successfully. The TSP 
containing VP2/6 or VP2/6/7 was able to induce serum IgG 
and fecal IgA in mice. VP2, VP6 and VP7 produced in to-
bacco plants can assemble into VLPs, which are morpho-
logically similar to native RV particles. It was very encour-
aging that RV VLPs containing VP7, a neutralizing antigen, 
were found in the transgenic plants, although the amount 
found was quite low. Since there were not enough RV VLPs 
available, we could not compare the immunogenicity among 
the mixture of VP2, VP6 and VP7 proteins, the RV VLPs 
formed by these three proteins and the attenuated RV. More 
research is required to improve the formation of the RV 
VLPs. 
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